Table 2.
Cox regression analysis to identify prognostic factors for HBsAg loss in off-treatment patients
| Variables | HR | 95% CI | p-value |
|---|---|---|---|
| Male | 1.674 | 0.244–11.475 | 0.600 |
| Over 30 years old | 0.703 | 0.095–5.183 | 0.730 |
| Baseline ALT > 4 × ULN U/L | 1.395 | 0.380–5.121 | 0.616 |
| Baseline HBV DNA < 2 × 106 IU/mL | 0.097 | 0.007–1.379 | 0.085 |
| Baseline HBsAg < 25,000 IU/mL | 7.799 | 2.903–20.947 | < 0.001 |
| On-treatment HBsAg decline > 1 log10 IU/mL at week 24 | 8.329 | 2.470–28.087 | 0.001 |
| On-treatment HBV DNA decline > 2 log10 IU/mL at week 24 | 12.726 | 0.627–258.244 | 0.098 |
| Duration of IFN over 1 year | 0.253 | 0.049–1.310 | 0.101 |
| EOT HBsAg ≤10 IU/mL | 7.918 | 2.453–25.556 | 0.001 |
ALT alanine aminotransferase, ULN upper limit of normal, IFN interferon, EOT end-of-treatment. P-values < 0.05 are shown in bold italics